Dan Leblanc

Daniel Leblanc has been the Chief Technology Officer at Ensoma since 2020. Prior to Ensoma, Daniel was at Flexion Therapeutics, where he led technical operations – leading to their first commercial product and the technical development of FX201.

Daniel has also held the roles of Director of Pharmaceutical Development at Merck Serono and spent 11 years at Alkermes, Inc., specializing in the characterization and development of manufacturing processes for novel drug delivery programs.

Daniel holds a B.S. from Syracuse University in chemical engineering and a joint M.S. from University of Pennsylvania School of Engineering and the Wharton School in technology management.